Cytokinetics Announces Three Late-Breaking Science Abstracts at the European Society of Cardiology (ESC) Congress 2026

About this update from Cytokinetics, Incorporated

Hot Line Presentation of Primary Results from ACACIA-HCM to Elaborate on Positive Topline Results in Patients with Non-Obstructive Hypertrophic Cardiomyopathy Company to Host In-Person and Virtual Investor Event to Discuss Results from Late-Breaking Science Presentations SOUTH SAN FRANCISCO, Calif., July 07, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced three Late Breaking Science abstracts were accepted for presentation at the European Society of Cardiology (ESC) Congress, taking place August 28-31 in Munich, Germany, including a Hot Line presentation of the primary results from ACACIA-HCM, the pivotal Phase 3 clinical trial of  aficamten in patients with non-obstructive hypertrophic cardiomyopathy (HCM). Hot Line and Late-Breaking Science Presentations Title: ACACIA-HCM: Aficamten for Symptomatic Nonobstructive Hypertrophic Cardiomyopathy Presenter : Ahmad Masri, M.D., M.S., Associate Professor of Medicine, Director of the Hypertrophic Cardiomyopathy Center at Oregon Health & Science University Date : Friday, August 28, 2026 Session Title : Hot Line 1 Session Time : 11:00 AM – 12:15 PM CEST Presentation Time : 11:45 – 11:55 AM CEST Location : Munich, Main Auditorium (Hall B3) Title: Effect of Aficamten on Cardiac Structure and Function in Patients with Symptomatic Nonobstructive Hypertrophic Cardiomyopathy - Results from the ACACIA-HCM Trial Presenter : Sheila Hegde, M.D., MPH, Assistant Professor, University of Texas Southwestern Medical Center – Dallas, TX and Affiliate Faculty, Brigham and Women's Hospital, Boston, MA Date : Saturday, August 29, 2026 Session Title : Late-Breaking Clinical Science: Hypertrophic Cardiomyopathy Session Time : 4:15 – 5:15 PM CEST Presentation Time : 4:15 – 4:30 PM CEST Location : Achgabat (Hall A3) Title: Aficamten vs. Metoprolol Monotherapy in Obstructive Hypertrophic Cardiomyopathy According to Pre-Trial Treatment in MAPLE-HCM Presenter : Fernando Dominguez, M.D., Ph.D., Consultant Cardiologist, Hospital Universitario Puerta De Hierro Majadahonda – Madrid, Spain Date : Saturday, August 29, 2026 Session Title : Late-Breaking Clinical Science: Hypertrophic Cardiomyopathy Session Time : 4:15 – 5:15 PM CEST Presentation Time : 4:30 – 4:45 PM CEST Location : Achgabat (Hall A3) Investor Event and Webcast Cytokinetics will host an in-person and virtual investor event onsite at ESC to discuss results from the Late-Breaking Science presentations at the Congress. Additional details including the date, time and registration information will be announced at a later date.

View stock analysis, news, and events for Cytokinetics, Incorporated